Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asparaginase Activity Monitoring in Adult ALL
NCT03668392Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: Number of patients with active serum Asparaginase at 8 months. Started Jun 2020; status: terminated.
02
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03668392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668392.